Similar pharmacodynamic effects were seen in OMP-C8 and OMP-C9 including an increase in the expression of regulators of Wnt signaling, PTPRO and ZNRF3. In OMP-C9, LGR5 expression was reduced (Fig. 4D) as has been observed in Rspo3 fusion CRC tumors after anti-Rspo3 treatment (Extended Fig. 1 and ref.3) These data demonstrate an effect of anti-Rspo3 treatment on Wnt target genes in the setting of APC or β-catenin mutated tumors. Here, LGR5 is linked to colorectal carcinoma.